Pulmonary Drugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022

Code : CMI1285

Pages :304

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Increasing tobacco smoking is expected to augment global pulmonary drugs market growth over forecast period.

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2021, tobacco smoking is the primary cause of COPD leading to around 90% of Chronic Obstructive Pulmonary Disease (COPD) cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma.For instance, in March 2022, according Centers for Disease Control (CDC), 30.8 billion adults in the U.S. smoked. Nearly 40 billion U.S. adults still smoke cigarettes, and an estimated 2.55 billion middle and high school students use at least one tobacco product, including e-cigarettes according statistical data provided in March 2022. For instance, September 2020, according to artoicle published in National Center for Biotechnology Information, every day, about 1,600 U.S. youth younger than 18 years smoke their first cigarette. Each year, nearly half a billion U.S. citizens die prematurely of smoking or exposure to secondhand smoke. Another 16 billion live with a serious illness caused by smoking. Each year, the U.S. spends more than $225 billion on medical care to treat smoking-related disease in adults.

Supportive government and non-government initiatives for preventing and curing pulmonary diseases are expected to accelerate the global pulmonary drugs market growth over the forecast period.

Global Pulmonary Drugs Market: Restraint

The major factors that hinder growth of the global pulmonary drugs market include stringent government regulations regarding pulmonary drugs approval. The strict regulatory scenario and the regulatory requirements of the drug delivery systems is presenting a challenge to market players because the pulmonary drug delivery systems are a combination of drug and device. Therefore, it is regulated under new provisions by governments of various countries. For instance, in April 2021, according to data published by Center for Disease Control, the (Prescription Drug User Fee Act) PDUFAVII reauthorization proposal described timely review of the safety and effectiveness of new drug applications (NDAs) and biologics license applications (BLAs) is central to the U.S. Food and Drug Administration (FDA)’s mission to protect and promote the public health – and Prescription Drug User Fee Act (PDUFA) is essential to these efforts.